Compare American Express Co (AXP) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs BioNTech SE - ADR — how do they compare? American Express Co trades at $341.53 (market cap $230.15B), while BioNTech SE - ADR trades at $93.06 (market cap $23.31B). The key difference: American Express Co is far larger — about 9.9× BioNTech SE - ADR's market cap, and American Express Co pays a 1.11% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| AXP | BNTX | |
|---|---|---|
Market Cap | $230.15B | $23.31B |
Sector | Financials | Health |
52-Week High | $384.82 | $119.34 |
52-Week Low | $292.27 | $83.89 |
Dividend Yield | 1.11% | — |
Enterprise Value | — | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXP trades at $341.25, up 0.7% on the day, with a bullish technical signal and strong support at $339. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.07% net margin. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus is a Buy with a $369.42 price target. News highlights Amex Ventures' AI investments and premium cardmember perks.
Outlook is positive given earnings momentum and strategic AI bets, but risks include rising debt levels and competitive pressure. The stock offers growth potential with a reasonable P/E of 20.68, though investors should watch for economic sensitivity in consumer spending.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
